Inogen Inc (NAS:INGN)
$ 8.61 -0.15 (-1.71%) Market Cap: 203.00 Mil Enterprise Value: 108.84 Mil PE Ratio: 0 PB Ratio: 1.06 GF Score: 67/100

Inogen Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 06:30PM GMT
Release Date Price: $22.16 (+1.42%)
Robert Justin Marcus
JPMorgan Chase & Co, Research Division - Analyst

Welcome, everyone. I'm Robbie Marcus, the med tech analyst at JPMorgan. Really happy to introduce our next presentation from Inogen, going to bring up Nabil Shabshab, the CEO, and then we'll do some Q&A after. Nabil?

Nabil Shabshab
Inogen, Inc. - CEO, President & Director

Thank you, Robbie, and thank you for having us here. Welcome, guys. So I'm going to maybe start with those who don't know Inogen that well with a very high-level description.

So we're a global med tech company that is focused on respiratory care, but deep into the oxygen therapy -- long-term oxygen therapy market for chronic respiratory conditions, COPD and beyond that.

As a company, we take our purpose, our true note very seriously, which is improving the lives through respiratory care. It's the globe that hosts the organization together, everybody wakes up every day with a very discerned focus on serving patients much better than the day before. And that's what drives us every day.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot